Loading...
XNAS
AEMD
Market cap9mUSD
Dec 05, Last price  
3.70USD
1D
-8.19%
1Q
412.47%
Jan 2017
-99.41%
Name

Aethlon Medical Inc

Chart & Performance

D1W1MN
XNAS:AEMD chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
35.52%
Rev. gr., 5y
%
Revenues
0k
0000001,359,6211,230,0041,623,769762,417886,572392,073149,625229,625650,187659,104294,165574,24500
Net income
-13m
L+9.67%
-2,920,183-6,024,545-4,140,264-6,084,158-4,573,315-5,711,435-8,111,340-4,892,040-13,357,232-6,797,157-4,872,329-7,276,113-5,679,558-6,194,719-6,373,948-7,886,709-10,416,091-12,029,786-12,208,000-13,388,089
CFO
-8m
L-24.52%
-1,584,281-1,718,904-2,104,272-1,777,388-1,977,517-1,968,333-1,841,355-2,098,857-2,138,971-5,049,414-4,329,307-3,505,900-3,910,680-4,293,433-5,197,608-6,764,940-9,767,157-10,505,128-10,129,810-7,645,532

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
IPO date
Mar 09, 1994
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT